Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.26 +1.29 (+2.81%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
News headline image
Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report ↗
CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game. 
Via Stocktwits
News headline image
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership. 
Via Benzinga
News headline image
Mangoceuticals Shares Soar Pre-market After Partnering with Eli Lilly, Novo Nordisk To Sell Obesity Drugs ↗
The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines. 
Via Stocktwits
1 Incredible Reason to Buy LLY's Stock in November ↗
Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher. 
Via The Motley Fool
Topics Government World Trade
News headline image
Eli Lilly Soars: A Pharmaceutical Giant's Breakout Fueled by Blockbuster Drugs and Strategic Vision
INDIANAPOLIS, IN – November 12, 2025 – Eli Lilly and Company (NYSE: LLY) is experiencing a monumental stock breakout today, sending ripples across the global financial markets. The pharmaceutical... 
Via MarketMinute
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study. 
Via Benzinga
News headline image
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch ↗
Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share. 
Via Benzinga
News headline image
Why Metsera's Share Price Is Plummeting This Week ↗
The biotech start-up's stock had been rising rapidly in 2025. 
Via The Motley Fool
‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗
Via Stocktwits
News headline image
AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today ↗
Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61. 
Via Benzinga
Topics Stocks
News headline image
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India ↗
Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? ↗
Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs. 
Via The Motley Fool
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion ↗
The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗
Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks. 
Via Stocktwits
News headline image
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump ↗
The companies announced a huge deal that will have implications for investors. 
Via The Motley Fool
Topics World Trade
News headline image
Should You Buy Novo Nordisk After the Huge Investor Update? ↗
Pharma companies are under pressure to lower prices in the U.S. 
Via The Motley Fool
News headline image
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock? ↗
The company continues to have a strong growth outlook ahead. 
Via The Motley Fool
News headline image
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors. ↗
Weight loss drugs generated about $10 billion for Lilly in the most recent quarter. 
Via The Motley Fool
Topics Government
News headline image
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance ↗
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard." 
Via Benzinga
News headline image
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy ↗
 
Via Benzinga
News headline image
Why Novo Nordisk Stock Is Sinking This Week ↗
The global drugmaker is facing some headwinds related to tough competition. 
Via The Motley Fool
Topics Government World Trade
News headline image
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment ↗
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment. 
Via Benzinga
News headline image
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs. 
Via Benzinga
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
News headline image
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage. 
Via Stocktwits
Topics Government World Trade
News headline image
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts ↗
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026. 
Via Benzinga
Topics Government
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.